Readying for market: The Digest’s 2016 8-Slide Guide to REG Life Sciences

In January 2014, REG acquired LS9 for a purchase price of up to $61.5 million. Most of the old LS9 team, including the entire R&D leadership group, joined the newly named REG Life Sciences, LLC. The technology has been substantially developed under REG’s management, with several molecules ready for commercialization in the next 2-3 years — as we saw in this recent investor presentation on the unit’s progress.